Refractory Lymphoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 35 expanded access programs, clinical trials, and compassionate use pathways listed for Refractory Lymphoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with refractory lymphoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 31 programs are currently active or recruiting, with the remaining 4 in other lifecycle stages. Sponsors actively running programs in this area include National Cancer Institute (NCI), Austin I Kim, Children's Oncology Group, Mayo Clinic, Reid Merryman, MD.
By recruiting status
Snapshot of where every Refractory Lymphoma program currently sits in its lifecycle.
- Active / Recruiting31
- Inactive4
Top sponsors
Organisations running the most Refractory Lymphoma programs in the directory.
- National Cancer Institute (NCI)31 programs
- Austin I Kim1 program
- Children's Oncology Group1 program
- Mayo Clinic1 program
- Reid Merryman, MD1 program
Refractory Lymphoma programs (35)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Elimusertib for Treating Solid Tumors That Have Returned or Are Resistant to Treatment — National Cancer Institute (NCI)
- Study on Epcoritamab, Zanubrutinib, and Rituximab for Treating Relapsed or Refractory Follicular Lymphoma — Reid Merryman, MD
- Study on Selpercatinib for Treating Advanced Cancers with RET Gene Changes in Children and Young Adults — National Cancer Institute (NCI)
- Study on Genetic Testing-Directed Targeted Therapy for Advanced Solid Tumors, Lymphomas, or Multiple Myeloma — National Cancer Institute (NCI)
- Study on Ado-Trastuzumab Emtansine for Cancers with HER2 Genetic Changes — National Cancer Institute (NCI)
- Study on Afatinib for Cancers with HER2 Genetic Changes (MATCH-Subprotocol B) — National Cancer Institute (NCI)
- Testing Afatinib for Treating Cancers with EGFR Genetic Changes — National Cancer Institute (NCI)
- Study on AZD1775 for Treating Cancers with BRCA Genetic Changes — National Cancer Institute (NCI)
- Study on AZD9291 for Treating Cancers with EGFR Genetic Changes — National Cancer Institute (NCI)
- Study on BVD-523FB (Ulixertinib) for Cancers with Specific Genetic Changes — National Cancer Institute (NCI)
- Study on Copanlisib for Treating Cancers with PIK3CA Mutations — National Cancer Institute (NCI)
- Study on Copanlisib for Treating Cancers with PTEN Gene Changes — National Cancer Institute (NCI)
- Study on Crizotinib for Cancers with ROS1 Genetic Changes (MATCH-Subprotocol G) — National Cancer Institute (NCI)
- Study on Crizotinib for Treating Cancers with MET Exon 14 Deletion Genetic Changes — National Cancer Institute (NCI)
- Study on GDC-0032 (Taselisib) for Treating Cancers with PIK3CA Genetic Changes — National Cancer Institute (NCI)
- Study on Vismodegib for Treating Cancers with Specific Genetic Mutations — National Cancer Institute (NCI)
- Study on GSK2636771 for Treating Cancers with PTEN Genetic Changes — National Cancer Institute (NCI)
- Testing GSK2636771 for Cancers with PTEN Loss of Expression — National Cancer Institute (NCI)
- Study on Ipatasertib for Treating Cancers with AKT Genetic Changes — National Cancer Institute (NCI)
- Study on Erdafitinib for Treating Cancers with FGFR Gene Amplifications — National Cancer Institute (NCI)
- Study on LOXO-101 for Treating Cancers with NTRK Genetic Changes — National Cancer Institute (NCI)
- Study on MLN0128 (TAK-228) for Cancers with mTOR Genetic Changes — National Cancer Institute (NCI)
- Study on MLN0128 (TAK-228) for Cancers with TSC1 or TSC2 Genetic Changes — National Cancer Institute (NCI)
- Study on Palbociclib as a Targeted Treatment for Cancers with CCND1, 2, or 3 Amplification — National Cancer Institute (NCI)
- Study on Palbociclib for Treating Cancers with CDK4 or CDK6 Gene Changes — National Cancer Institute (NCI)
- Study on Sunitinib for Treating Cancers with cKIT Genetic Changes — National Cancer Institute (NCI)
- Testing Trametinib and Dabrafenib for Cancers with BRAF Genetic Changes — National Cancer Institute (NCI)
- Study on Trametinib for Treating Cancers with BRAF Genetic Changes — National Cancer Institute (NCI)
- Study on Trametinib for Cancers with GNAQ or GNA11 Genetic Changes — National Cancer Institute (NCI)
- Testing Trametinib for Cancers with NF1 Genetic Changes (MATCH-Subprotocol S1) — National Cancer Institute (NCI)
- Study on VS-6063 (Defactinib) for Cancers with NF2 Genetic Changes — National Cancer Institute (NCI)
- Study on Ascorbic Acid and Chemotherapy for Treating Relapsed or Hard-to-Treat Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia — Mayo Clinic
- Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Relapsed/Refractory and Untreated Mantle Cell Lymphoma — Austin I Kim
- CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma — Children's Oncology Group
- Testing a New Drug Combination, Entinostat and ZEN003694, for Advanced and Hard-to-Treat Cancers — National Cancer Institute (NCI)
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Refractory Lymphoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.